Aptose Biosciences Inc. (NASDAQ:APTO) Short Interest Update

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) was the recipient of a significant drop in short interest in February. As of February 15th, there was short interest totalling 74,900 shares, a drop of 92.5% from the January 31st total of 993,200 shares. Currently, 3.7% of the company’s stock are short sold. Based on an average trading volume of 397,700 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Aptose Biosciences stock. Sigma Planning Corp grew its stake in shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 71.3% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 401,750 shares of the biotechnology company’s stock after buying an additional 167,282 shares during the period. Sigma Planning Corp owned 2.22% of Aptose Biosciences worth $165,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 26.62% of the company’s stock.

Aptose Biosciences Trading Down 4.4 %

APTO stock traded down $0.16 during trading hours on Thursday, hitting $3.48. 48,469 shares of the stock were exchanged, compared to its average volume of 328,531. Aptose Biosciences has a 12 month low of $3.11 and a 12 month high of $58.18. The company has a 50-day simple moving average of $6.06 and a two-hundred day simple moving average of $8.95. The firm has a market capitalization of $223.76 million, a P/E ratio of -1.17 and a beta of 0.88.

Analysts Set New Price Targets

APTO has been the topic of several recent research reports. StockNews.com initiated coverage on shares of Aptose Biosciences in a report on Tuesday. They issued a “hold” rating on the stock. HC Wainwright reiterated a “buy” rating and set a $60.00 price objective on shares of Aptose Biosciences in a research report on Wednesday, February 12th.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.